Gibt es pflanzliche Alternativen zu chemisch definierten Antihypertensiva?

ZUSAMMENFASSUNG

In 3 aktuellen Leitlinien zur Hypertonie wird aufgrund von neueren Studien eine noch stärkere Blutdrucksenkung als bisher gefordert. Zudem wird immer deutlicher, dass eine Monotherapie mit einem konventionellen Antihypertensivum das Risikoprofil für kardiovaskuläre Erkrankungen nur unzureichend bessert und daher Kombinationen mit anderen Wirksubstanzen wie z. B. Statinen erforderlich sind. Die diesbezügliche pleiotrope Wirkung von z. B. Hibiskusblüten, grünen Kaffeebohnen, Knoblauchzwiebeln, Roter Bete, Weißdornblättern und -blüten oder Zimtrinde wird jedoch bisher kaum wahrgenommen. Im vorliegenden Artikel werden systematische Reviews und Metaanalysen zu ihrem antihypertensiven Potenzial vorgestellt.

Abstract

Based on recent studies, three current guidelines on hypertension call for an even greater reduction in blood pressure than before. It is also becoming increasingly clear that monotherapy with a conventional antihypertensive drug does not sufficiently improve the risk profile for cardiovascular diseases, and that combinations with other active substances such as statins are therefore necessary. However, the pleiotropic effect of e. g. hibiscus flowers, green coffee beans, garlic bulbs, beet, hawthorn leaves and flowers or cinnamon bark in this respect has hardly been recognized to date. This article presents systematic reviews and meta-analyses of their antihypertensive potential.

Keywords

Hypertension - cardiovascular risk factors - medicinal guidelines - phytotherapy - antihypertensive herbal drugs - systematic reviews

Schlüsselwörter

Hypertonie - kardiovaskuläre Risikofaktoren - medizinische Leitlinien - Phytotherapie - pflanzliche Antihypertensiva - systematische Reviews

Publication History

Article published online:
27 August 2025

• Literatur

• 1 Bundesärztekammer (BÄK), Kassenärztliche Bundesvereinigung (KBV), Arbeitsgemeinschaft der Wissenschaftlichen Medizinischen Fachgesellschaften (AWMF). Nationale VersorgungsLeitlinie Hypertonie – Langfassung, Version 1.0. 2023. Zugriff am 06.06.2025 unter http://www.leitlinien.de/hypertonie
• 2 McEvoy JW, McCarthy CP, Bruno RM. et al. 2024 ESC Guidelines for the management of elevated blood pressure and hypertension. Eur Heart J 2024; 45: 3912-4018
• 3 Mancia G, Kreutz R, Brunström M. et al. 2023 ESH Guidelines for the management of arterial hypertension. The Task Force for the management of arterial hypertension of the European Society of Hypertension. J Hypertension 2023; 41: 1874-2071
• 4 Williamson JD, Supiano MA, Applegate WB. et al. Intensive vs standard blood pressure control and cardiovascular disease outcomes in adults aged≥75 years. A randomized clinical trial. JAMA 2016; 315: 2673-2682
• 5 Zhang W, Zhang S, Deng Y. et al. Trial of intensive blood-pressure control in older patients with hypertension. N Engl J Med 2021; 385: 1268-1279
• 6 Liu J, Wang B, Li Y. et al. Rationale and design of the Effects of intensive Systolic blood Pressure lowering treatment in reducing RIsk of vascular evenTs (ESPRIT): A multicenter open-label randomized controlled trial. Am Heart J 2023; 257: 93-102
• 7 Jackson R, Lawes CM, Bennett DA. et al. Treatment with drugs to lower blood pressure and blood cholesterol based on an individual’s absolute cardiovascular risk. Lancet 2005; 365: 434-441
• 8 Woolf KJ, John D, Bisognano JD. Nondrug interventions for treatment of hypertension. Clin Hypertens (Greenwich) 2011; 13: 829-835
• 9 Sindi HA, Marshall LJ, Morgan MR. Comparative chemical and biochemical analysis of extracts of Hibiscus sabdariffa . Food Chem 2014; 164: 23-29
• 10 Norouzzadeh M, Rashedi MH, Azizi MH. et al. Efficacy and safety of Hibiscus sabdariffa in cardiometabolic health: An overview of reviews and updated dose-response meta-analysis. Complement Ther Med 2025; 89: 103135
• 11 Abdelmonem M, Ebada MA, Diab S. et al. Efficacy of Hibiscus sabdariffa on reducing blood pressure in patients with mild-to-moderate hypertension: a systematic review and meta-analysis of published randomized controlled trials. J Cardiovasc Pharm 2022; 79: e64-e74
• 12 Herrera-Arellano A, Miranda-Sánchez J, Avila-Castro P. et al. Clinical effects produced by a standardized herbal medicinal product of Hibiscus sabdariffa on patients with hypertension. A randomized, double-blind, lisinopril-controlled clinical trial. Planta Med 2007; 73: 6-12
• 13 Tajik N, Tajik M, Mack I. et al. The potential effects of chlorogenic acid, the main phenolic components in coffee, on health: A comprehensive review of the literature. Eur J Nutr 2017; 56: 2215-2244
• 14 Giglio RV, Patti AM, Cicero AFG. et al. Polyphenols: Potential use in the prevention and treatment of cardiovascular diseases. Curr Pharm Des 2018; 24: 239-258
• 15 Pourmasoumi M, Hadi A, Marx W. et al. The effect of green coffee bean extract on cardiovascular risk factors: A systematic review and meta-analysis. Adv Exp Med Biol 2021; 1328: 323-345
• 16 Samavat S, Ashtary-Larky D, Naeini F. et al. The effects of green coffee bean extract on blood pressure and heart rate: A systematic review and dose-response meta-analysis of randomized controlled trials. Diabetes Metab Synd 2024; 18: 103120
• 17 Batiha GE, Beshbishy AM, Wasef LG. Chemical constituents and pharmacological activities of garlic (Allium sativum L.): A review. Nutrients 2020; 12: 872
• 18 Benavides GA, Squadrito GL, Mills RW. et al. Hydrogen sulfide mediates the vasoactivity of garlic. Proc Natl Acad Sci U S A 2007; 104: 17977-17982
• 19 Sharifi AM, Darabi R, Akbarloo N. Investigation of antihypertensive mechanism of garlic in 2K1C hypertensive rat. J Ethnopharmacol 2003; 86: 219-24
• 20 Gebhardt R, Beck H, Wagner KG. Inhibition of cholesterol biosynthesis by allicin and ajoene in rat hepatocytes and HepG2 cells. Biochim Biophys Acta 1994; 1213: 57-62
• 21 Gupta N, Porter TD. Garlic and garlic-derived compounds inhibit human squalene monooxygenase. J Nutr 2001; 131: 1662-1667
• 22 Focke M, Feld A, Lichtenthaler K. Allicin, a naturally occurring antibiotic from garlic, specifically inhibits acetyl-CoA synthetase. FEBS Lett 1990; 261: 106-108
• 23 European Union herbal monograph on Allium sativum L., bulbus. EMA/HMPC/329435/2024
• 24 Matsutomo T, Ushijima M, Kodera Y. et al. Metabolomic study on the antihypertensive effect of S-1-propenylcysteine in spontaneously hypertensive rats using liquid chromatography coupled with quadrupole-Orbitrap mass spectrometry. J Chromatogr B 2017; 1046: 147-155
• 25 Xiong XJ, Wang PQ, Li SJ. et al. Garlic for hypertension: A systematic review and meta-analysis of randomized controlled trials. Phytomedicine 2015; 22: 352-361
• 26 Wang HP, Yang J, Qin LQ. et al. Effect of garlic on blood pressure: a meta-analysis. J Clin Hypertens (Greenwich) 2015; 17: 223-231
• 27 Ried K. Garlic lowers blood pressure in hypertensive individuals, regulates serum cholesterol, and stimulates immunity: An updated meta-analysis and review. J Nutr 2016; 146: 389S-396S
• 28 Saadh MJ, Kariem M, Shukla M. et al. Effects of aged garlic extract on blood pressure in hypertensive patients: A systematic review and meta-analysis of randomized controlled trials. Prostaglandins Other Lipid Mediat 2024; 175: 106914
• 29 Gilchrist M, Winyard PG, Aizawa K. et al. Effect of dietary nitrate on blood pressure, endothelial function, and insulin sensitivity in type 2 diabetes. Free Radic Biol Med 2013; 60: 89-97
• 30 Bahadoran Z, Mirmiran P, Kabir A. et al. The nitrate-independent blood pressure-Lowering effect of beetroot juice: A systematic review and meta-analysis. Adv Nutr 2017; 8: 830-838
• 31 Draft assessment report on Crataegus monogyna Jacq. (Lindm.), C. laevigata (Poir.) DC. or their hybrids; C. pentagyna Waldst. et Kit. ex Willd.; C. azarolus L. EMA/HMPC/116318/2024
• 32 Draft European Union herbal monograph on Crataegus monogyna Jacq. (Lindm.), C. laevigata (Poir.) DC. or their hybrids; C. pentagyna Waldst. et Kit. ex Willd.; C. azarolus L. Reference Number: EMA/HMPC/234781/2024
• 33 Clouda A, Vilcinsa D, McEwen B. The effect of hawthorn (Crataegus spp.) on blood pressure: A systematic review. Adv. Integr Med 2020; 7: 167-175
• 34 Hajimonfarednejad M, Ostovar M, Raee MJ. et al. Cinnamon: a systematic review of adverse events. Clin Nutr 2019; 38: 594e602
• 35 Hadi A, Campbell MS, Hassani B. et al. The effect of cinnamon supplementation on blood pressure in adults: A systematic review and meta-analysis of randomized controlled trials. Clinical Nutrition ESPEN 2020; 36: 10-16
• 36 Sleight P, Yusuf S, Pogue J. et al. Heart Outcomes Prevention Evaluation (HOPE) study. Blood-pressure reduction and cardiovascular risk in HOPE study. The Lancet 2001; 358: 2130-2131
• 37 Hartley A, Rostamian S, Kaura A. et al. The relationship of baseline high-sensitivity C-reactive protein with incident cardiovascular events and all-cause mortality over 20 years. BioMedicine 2025; 117: 105786
• 38 Wissenschaftliches Institut der AOK (WIdO) (11. April, 2025). 12-Monats-Prävalenz von Bluthochdruck in Deutschland nach Alter und Geschlecht im Jahr 2023 (in Prozent) [Graph]. In: Statista. Zugriff am 30.06.2025 unter https://de.statista.com/statistik/daten/studie/1394226/umfrage/12-monats-praevalenz-von-bluthochdruck-nach-alter-und-geschlecht-in-deutschland/
• 39 European Food Safety Authority. Health claims (Art. 13), Questions on hold Botanical claims [Excel-Datei]. Zugriff am 30.06.2025 unter https://www.efsa.europa.eu/sites/default/files/2021-06/questions-on-hold-botanicals-claims.xlsx